Back to today’s briefing

Story perspectives

Baxdrostat Lowers Blood Pressure in Resistant Patients by 10 mmHg

4/4/2026

34 5 Full Breakdown

Summary

Story summary

Baxdrostat reduced blood pressure in patients unresponsive to existing treatments in a Phase III trial led by Professor Bryan Williams at University College London (UCL).
The nearly 800-participant study showed a 9–10 mmHg drop after 12 weeks.
About 40% reached healthy blood pressure, compared with under 20% on placebo.
Findings were presented at the European Society of Cardiology Congress 2025 and published in the New England Journal of Medicine.

1 of 1

Story summary

Baxdrostat reduced blood pressure in patients unresponsive to existing treatments in a Phase III trial led by Professor Bryan Williams at University College London (UCL).
The nearly 800-participant study showed a 9–10 mmHg drop after 12 weeks.
About 40% reached healthy blood pressure, compared with under 20% on placebo.
Findings were presented at the European Society of Cardiology Congress 2025 and published in the New England Journal of Medicine.